歐舒丹(00973.HK)急漲15%創逾十個月高 中績後獲花旗及野村升價
歐舒丹(00973.HK)中績少賺37.5%,花旗調高歐舒丹目標價至19元和維持「買入」評級,以及升公司未來三年盈測,以反映公司較高經營溢利率預期;野村績後也上調歐舒丹目標價至21.1元及重申「買入」評級,以反映公司利潤率前景樂觀。該股今天高見19.2元,創逾十個月高,現造18.8元,回升15%,成交額增至1,627萬元。
歐舒丹昨天收市後公布,截至9月底止中期純利按年(下同)減少37.5%至1.561.3萬歐元,營業額6.17億歐元,按報告匯率及固定匯率分別減少15.2%及13.1%;經營溢利減少21.2%至3,290萬歐元;毛利跌14.2%至5.06億歐元,毛利率按年增加0.9個百分點至82.1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.